Why is Navitas Semiconductor stock sliding today?

Navitas shares slid 6.4% in the morning after Wolfspeed filed a U.S. patent infringement lawsuit alleging Navitas’ core GaNFast/GaNSlim/GaNSafe and GeneSiC/SiCPAK products infringe five foundational wide-bandgap technology patents. The legal overhang adds to dilution concerns from a $500 million at-the-market equity shelf and a sharp revenue contraction over the past year, while the stock opened around $13.40 and hit a $12.88 session low. With the next catalyst not until Q2 2026 earnings (Jul 27, expected -$0.05 EPS on ~$10M revenue) and the broader market softer (S&P 500 -0.6%, Dow -1.3%, Nasdaq -0.5%), selling pressure intensified despite wide-ranging analyst targets ($13 to $21).

Analysis

This is less a one-day headline than a financing and customer-qualification event. For a company still trying to prove product-market fit and stabilize revenue, an IP challenge against the core catalog raises the probability of longer sales cycles, higher legal spend, and customer pause behavior: OEMs in power semis hate supply continuity risk, so even if the claims are weak, design wins can migrate toward larger incumbents with deeper patent cross-licenses and manufacturing redundancy. That creates a second-order benefit for diversified names like ON, Infineon, and STM more than for any direct plaintiff victory.

The market is likely underpricing the dilution/solvency interaction. When a high-beta name is already leaning on an equity shelf and negative operating leverage, litigation doesn’t just add expense — it can tighten access to capital by widening the gap between reported revenue and the cash needed to fund defense, working capital, and customer support. Near term, the first catalyst is not the trial outcome but whether management is forced to guide on legal spend, reserve assumptions, or delayed commercial ramps into the July print; that matters more than the complaint itself.

Contrarian view: the knee-jerk selloff may be larger than the fundamental damage if the case is mainly a leverage play and no injunction is realistic. If the patents are narrow or easily designed around, the stock can rebound quickly on procedural wins or a cheap settlement. But the burden of proof is on bulls: absent evidence of stable demand and reduced cash burn, NVTS remains a funding story first and a technology story second.

Key Decisions for Investors

• Short NVTS into strength or via put spreads ahead of the July 27 earnings window; thesis is legal overhang + dilution + weak operating momentum. Risk/reward is attractive if the stock re-rates toward recent support, but cover immediately on any disclosure that the case is dismissed, stayed, or settled cheaply.
• Pair trade: long ON or IFNNY vs short NVTS for 1-3 months. The long leg captures migration of skeptical customers toward larger, patent-hardened suppliers while limiting single-name legal risk; this is a relative-value trade, not an outright semiconductor market call.
• Avoid chasing WOLF long on the lawsuit alone. The plaintiff may gain leverage, but the balance-sheet and cash-flow profile still dominates the equity; use it only as a watchlist name for settlement optionality, not a conviction long.
• Set an alert for July earnings and any guidance on legal expense, cash burn, or capital raising. A meaningfully reduced cash burn or no mention of accelerating dilution would be the first credible falsifier for the bearish thesis.